Mesa Reports Q3 Revenue of $65.126M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Should l Buy MLAB?
Reports Q3 revenue $65.126M, consensus $63.23M. "Steady execution and relatively stable markets across Europe and North America helped deliver 3.6% organic revenues growth in 3Q26 versus the prior year, or 5.7% when excluding CG China revenues. Total company growth was 7.2% sequentially, well within our expected growth range. Strong growth in BPD, continued growth in CG excluding China, and a recovery towards normal SDC deliveries overcame strong but expected headwinds in CG China. For the first nine months of FY26, we delivered 3.7% organic revenues growth, but 6.6% when excluding CG China revenues. With continued strong execution across the business and less impactful CG China compares moving forward, we expect our positive momentum to continue in 4Q26" said Gary Owens, Chief Executive Officer of Mesa.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLAB
Wall Street analysts forecast MLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLAB is 99.00 USD with a low forecast of 83.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 93.270
Low
83.00
Averages
99.00
High
115.00
Current: 93.270
Low
83.00
Averages
99.00
High
115.00
About MLAB
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mesa Laboratories Q4 Earnings Exceed Expectations
- Earnings Highlights: Mesa Laboratories reported a Q4 GAAP EPS of $0.65, beating expectations by $0.37, indicating a significant enhancement in profitability and reflecting the company's strengthened competitive position in the market.
- Revenue Growth: The company achieved Q4 revenue of $65.13 million, a 3.6% year-over-year increase, surpassing market expectations by $1.9 million, demonstrating sustained demand and steady market share growth in the medical device sector.
- Core Business Performance: On a non-GAAP basis, core organic revenue growth was 1.2%, while adjusted operating income (AOI) increased by 17.6% to $17.072 million, further solidifying the company's profitability within the industry.
- Excluding Unusual Items: Excluding CG China revenues, the non-GAAP organic revenue growth rate was 5.7%, showcasing Mesa Laboratories' robust performance in global markets, particularly in the diagnostics sector's ongoing expansion.
See More
Mesa Laboratories Declares $0.16 Quarterly Dividend Per Share
- Quarterly Dividend Announcement: Mesa Laboratories has declared a quarterly dividend of $0.16 per share of common stock, payable on March 16, 2026, which aims to reward shareholders and enhance investor confidence.
- Shareholder Record Date: The dividend will be distributed to shareholders of record at the close of business on February 28, 2026, ensuring eligible shareholders receive their returns promptly, thereby strengthening the company's relationship with investors.
- Company Background: Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, dedicated to improving product integrity and safety.
- Forward-Looking Statements: The company cautions investors about the risks and uncertainties associated with forward-looking statements, emphasizing that actual results may differ significantly from expectations, ensuring transparency and compliance.
See More
Mesa Labs CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
- Conference Participation: Mesa Laboratories' CEO Gary Owens and CFO John Sakys will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's leadership in life science tools and critical quality control solutions.
- Live Webcast: The formal presentation is scheduled for 4:30 p.m. Pacific Time, and will be accessible via a live webcast, enhancing investor transparency and engagement with the company.
- Investor Relations: An archived replay of the webcast will be available on Mesa Labs' Investor Relations website after the presentation, ensuring that investors who cannot attend live can still access key information, thereby improving communication efficiency with stakeholders.
- Company Background: Mesa Laboratories is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries, committed to enhancing product integrity and patient safety, further solidifying its market position.
See More
Mesa Laboratories to Present at 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: Mesa Laboratories' CEO Gary Owens and CFO John Sakys will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's leadership in life science tools and critical quality control solutions.
- Schedule Details: The formal presentation is set for 4:30 PM Pacific Time, which is expected to attract attention from investors and industry experts, further enhancing the company's visibility in the healthcare sector.
- Live Webcast: The presentation will be accessible via a live webcast on Mesa Laboratories' Investor Relations website, allowing global investors to receive real-time updates, thereby increasing transparency and investor confidence.
- Post-Presentation Replay: An archived replay of the webcast will be available through the same link after the presentation, ensuring that investors who cannot attend live can still access key information, promoting ongoing engagement between the company and its investors.
See More
Mesa Laboratories to Release Q3 FY2026 Financial Results on February 3, 2026
- Earnings Release Schedule: Mesa Laboratories is set to announce its Q3 FY2026 financial results on February 3, 2026, at 8:00 A.M. ET, which will provide investors with critical performance data to assess the company's financial health.
- Industry Leadership: As a global leader in the design and manufacture of life science tools and critical quality control solutions, Mesa serves the pharmaceutical, healthcare, and medical device industries, aiming to ensure product integrity and enhance patient and worker safety.
- Customer Value Enhancement: Mesa's products and services not only help clients improve product quality but also focus on enhancing the quality of life worldwide, reflecting the company's significance and impact within the industry.
- Management Contact Information: CEO Gary Owens and CFO John Sakys are available for contact, further enhancing communication with investors to ensure transparency and trust.
See More
Mesa Laboratories Schedules Q3 FY2026 Financial Results Release
- Earnings Release Schedule: Mesa Laboratories plans to release its Q3 FY2026 financial results on February 3, 2026, at 8:00 A.M. ET, demonstrating the company's commitment to transparency and investor communication.
- Industry Leadership: As a global leader in life science tools and critical quality control solutions, Mesa provides essential products in the pharmaceutical, healthcare, and medical device sectors, ensuring product integrity and enhancing patient and worker safety.
- Customer Service Commitment: Mesa is dedicated to improving quality of life worldwide through its products and services, reflecting the company's strategic goal of meeting customer needs and raising industry standards.
- Executive Contact Information: CEO Gary Owens and CFO John Sakys can be reached at 303-987-8000, further enhancing communication channels with investors and stakeholders.
See More
Mesa Laboratories Q4 Earnings Exceed Expectations
- Earnings Highlights: Mesa Laboratories reported a Q4 GAAP EPS of $0.65, beating expectations by $0.37, indicating a significant enhancement in profitability and reflecting the company's strengthened competitive position in the market.
- Revenue Growth: The company achieved Q4 revenue of $65.13 million, a 3.6% year-over-year increase, surpassing market expectations by $1.9 million, demonstrating sustained demand and steady market share growth in the medical device sector.
- Core Business Performance: On a non-GAAP basis, core organic revenue growth was 1.2%, while adjusted operating income (AOI) increased by 17.6% to $17.072 million, further solidifying the company's profitability within the industry.
- Excluding Unusual Items: Excluding CG China revenues, the non-GAAP organic revenue growth rate was 5.7%, showcasing Mesa Laboratories' robust performance in global markets, particularly in the diagnostics sector's ongoing expansion.
See More
Mesa Laboratories Declares $0.16 Quarterly Dividend Per Share
- Quarterly Dividend Announcement: Mesa Laboratories has declared a quarterly dividend of $0.16 per share of common stock, payable on March 16, 2026, which aims to reward shareholders and enhance investor confidence.
- Shareholder Record Date: The dividend will be distributed to shareholders of record at the close of business on February 28, 2026, ensuring eligible shareholders receive their returns promptly, thereby strengthening the company's relationship with investors.
- Company Background: Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, dedicated to improving product integrity and safety.
- Forward-Looking Statements: The company cautions investors about the risks and uncertainties associated with forward-looking statements, emphasizing that actual results may differ significantly from expectations, ensuring transparency and compliance.
See More
Mesa Labs CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
- Conference Participation: Mesa Laboratories' CEO Gary Owens and CFO John Sakys will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's leadership in life science tools and critical quality control solutions.
- Live Webcast: The formal presentation is scheduled for 4:30 p.m. Pacific Time, and will be accessible via a live webcast, enhancing investor transparency and engagement with the company.
- Investor Relations: An archived replay of the webcast will be available on Mesa Labs' Investor Relations website after the presentation, ensuring that investors who cannot attend live can still access key information, thereby improving communication efficiency with stakeholders.
- Company Background: Mesa Laboratories is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries, committed to enhancing product integrity and patient safety, further solidifying its market position.
See More
Mesa Laboratories to Present at 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: Mesa Laboratories' CEO Gary Owens and CFO John Sakys will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's leadership in life science tools and critical quality control solutions.
- Schedule Details: The formal presentation is set for 4:30 PM Pacific Time, which is expected to attract attention from investors and industry experts, further enhancing the company's visibility in the healthcare sector.
- Live Webcast: The presentation will be accessible via a live webcast on Mesa Laboratories' Investor Relations website, allowing global investors to receive real-time updates, thereby increasing transparency and investor confidence.
- Post-Presentation Replay: An archived replay of the webcast will be available through the same link after the presentation, ensuring that investors who cannot attend live can still access key information, promoting ongoing engagement between the company and its investors.
See More
Mesa Laboratories to Release Q3 FY2026 Financial Results on February 3, 2026
- Earnings Release Schedule: Mesa Laboratories is set to announce its Q3 FY2026 financial results on February 3, 2026, at 8:00 A.M. ET, which will provide investors with critical performance data to assess the company's financial health.
- Industry Leadership: As a global leader in the design and manufacture of life science tools and critical quality control solutions, Mesa serves the pharmaceutical, healthcare, and medical device industries, aiming to ensure product integrity and enhance patient and worker safety.
- Customer Value Enhancement: Mesa's products and services not only help clients improve product quality but also focus on enhancing the quality of life worldwide, reflecting the company's significance and impact within the industry.
- Management Contact Information: CEO Gary Owens and CFO John Sakys are available for contact, further enhancing communication with investors to ensure transparency and trust.
See More
Mesa Laboratories Schedules Q3 FY2026 Financial Results Release
- Earnings Release Schedule: Mesa Laboratories plans to release its Q3 FY2026 financial results on February 3, 2026, at 8:00 A.M. ET, demonstrating the company's commitment to transparency and investor communication.
- Industry Leadership: As a global leader in life science tools and critical quality control solutions, Mesa provides essential products in the pharmaceutical, healthcare, and medical device sectors, ensuring product integrity and enhancing patient and worker safety.
- Customer Service Commitment: Mesa is dedicated to improving quality of life worldwide through its products and services, reflecting the company's strategic goal of meeting customer needs and raising industry standards.
- Executive Contact Information: CEO Gary Owens and CFO John Sakys can be reached at 303-987-8000, further enhancing communication channels with investors and stakeholders.
See More
